Background OnabotulinumtoxinA has demonstrated significant benefit in adult focal spasticity. This study reviews the injection patterns (i.e., muscle distribution, dosing) of onabotulinumtoxinA for ...

The FDA has approved the expanded use of Botox® (onabotulinumtoxinA; Allergan) for the treatment of spasticity in pediatric patients aged ≥2 years, including those with lower limb spasticity caused by ...

Many people with multiple sclerosis have stiff muscles and spasms, a condition called spasticity. It happens mostly in the muscles of the legs and arms, and it may keep you from moving your limbs ...

The involuntary muscle spasms that occur as a result of neuromotor disorders and spinal cord injury can have dangerous consequences for affected individuals. New findings shed light on one mechanism ...

Spasticity most often develops in upper motor neuron types of injuries. It is a motor disorder defined as velocity dependent, increased resistance to passive muscle stretch. It is an exaggeration of ...

Researchers have made a significant advancement in the field of spinal cord injury research, developing a novel optogenetic mouse model that could lead to improved treatments for limb spasticity.

The global Spasticity Treatment Market is worth US$ 13.1 Billion as of now and is expected to reach US$ 28.4 Billion by the year 2033 at a CAGR of 8.1% between 2023 and 2033. Spasticity is turning out ...

In experiments with mice, researchers have studied neuronal mechanisms and found a way to by and large prevent spasticity from developing after spinal cord injuries. A new study shows that the ...

Spasticity, a phenomenon associated with the upper motor neuron syndrome, was defined by James W. Lance as "a motor disorder characterized by a velocity-dependent increase in tonic stretch reflex ...